A practical reference on reverse-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-01. Anything still debated is marked as such rather than presented as settled.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Preclinical and early clinical studies have been started to examine bortezomib's effectiveness in treating other B-cell-related cancers, particularly some types of non-Hodgkin's lymphoma. Clinical results also seem to justify use of proteasome inhibitor combined with chemotherapy, for B-cell acute lymphoblastic leukemia Proteasome inhibitors can kill some types of cultured leukemia cells that are resistant to glucocorticoids. The molecule ritonavir, marketed as Norvir, was developed as a protease inhibitor and used to target HIV infection. However, it has been shown to inhibit proteasomes as well as free proteases; to be specific, the chymotrypsin-like activity of the proteasome is inhibited by ritonavir, while the trypsin-like activity is somewhat enhanced. Studies in animal models suggest that ritonavir may have inhibitory effects on the growth of glioma cells. Proteasome inhibitors have also shown promise in treating autoimmune diseases in animal models. For example, studies in mice bearing human skin grafts found a reduction in the size of lesions from psoriasis after treatment with a proteasome inhibitor. Inhibitors also show positive effects in rodent models of asthma. Labeling and inhibition of the proteasome is also of interest in laboratory settings for both in vitro and in vivo study of proteasomal activity in cells. The most commonly used laboratory inhibitors are lactacystin and the peptide aldehyde MG132 initially developed by Goldberg lab. Fluorescent inhibitors have also been developed to specifically label the active sites of the assembled proteasome.
Other advantages of the NPT approach are that it is fast and convenient, usually less painful, and offers, in home use, the ability for patients to measure their own INRs when required. Among its problems are that quite a steady hand is needed to deliver the blood to the exact spot, that some patients find the finger-pricking difficult, and that the cost of the test strips must also be taken into account. In the UK these are available on prescription so that elderly and unwaged people will not pay for them and others will pay only a standard prescription charge, which at the moment represents only about 20% of the retail price of the strips. In the US, NPT in the home is currently reimbursed by Medicare for patients with mechanical heart valves, while private insurers may cover for other indications. Medicare is now covering home testing for patients with chronic atrial fibrillation. Home testing requires a doctor's prescription and that the meter and supplies are obtained from a Medicare-approved Independent Diagnostic Testing Facility (IDTF). There is some evidence to suggest that NPT may be less accurate for certain patients, for example those who have the lupus anticoagulant.
The quality of gamma-camera PET imaging is lower, and the scans take longer to acquire. Alternative methods of medical imaging include single-photon emission computed tomography (SPECT), computed tomography (CT), magnetic resonance imaging (MRI) and functional magnetic resonance imaging (fMRI), and ultrasound. SPECT is an imaging technique similar to PET that uses radioligands to detect molecules in the body.
Sources: en.wikipedia.org
==== Other early Americans ==== American officer John Parker Boyd partook in the Battle of Kharda, fighting on the side of the Nizam of Hyderabad. American Founding Father Aaron Burr had a relationship with an East Indian woman named Mary Emmons, who was most likely from the Indian city of Calcutta. Together, they had two children, including John Pierre Burr. Dudley Leavitt Pickman was an early American trader with India who founded the East India Marine Society. Fitzedward Hall was the first American to edit a Sanskrit text.
Coordination complexes have been known since the beginning of modern chemistry. Early well-known coordination complexes include dyes such as Prussian blue. Their properties were first well understood in the late 1800s, following the 1869 work of Christian Wilhelm Blomstrand. Blomstrand developed what has come to be known as the complex ion chain theory. In considering metal amine complexes, he theorized that the ammonia molecules compensated for the charge of the ion by forming chains of the type [(NH3)X]X+, where X is the coordination number of the metal ion. He compared his theoretical ammonia chains to hydrocarbons of the form (CH2)X. Following this theory, Danish scientist Sophus Mads Jørgensen made improvements to it. In his version of the theory, Jørgensen claimed that when a molecule dissociates in a solution there were two possible outcomes: the ions would bind via the ammonia chains Blomstrand had described or the ions would bind directly to the metal. It was not until 1893 that the most widely accepted version of the theory today was published by Alfred Werner. Werner's work included two important changes to the Blomstrand theory. The first was that Werner described the two possibilities in terms of location in the coordination sphere. He claimed that if the ions were to form a chain, this would occur outside of the coordination sphere while the ions that bound directly to the metal would do so within the coordination sphere. In one of his most important discoveries however Werner disproved the majority of the chain theory.
{\displaystyle {\begin{aligned}{\cfrac {V_{\max }}{1+{\cfrac {\ce {[I]}}{K_{i}}}}}&={V_{\max }}\left({\cfrac {K_{i}}{K_{i}+[{\ce {I}}]}}\right)&&{\text{multiply by }}{\cfrac {K_{i}}{K_{i}}}=1\\&={V_{\max }}\left({\cfrac {K_{i}+[{\ce {I}}]-[{\ce {I}}]}{K_{i}+[{\ce {I}}]}}\right)&&{\text{add }}[{\ce {I}}]-[{\ce {I}}]=0{\text{ to numerator}}\\&={V_{\max }}\left(1-{\cfrac {[{\ce {I}}]}{K_{i}+[{\ce {I}}]}}\right)&&{\text{simplify }}{\cfrac {K_{i}+[{\ce {I}}]}{K_{i}+[{\ce {I}}]}}=1\\&=V_{\max }-V_{\max }{\cfrac {\ce {[I]}}{K_{i}+[{\ce {I}}]}}&&{\text{multiply out by }}V_{\max }\end{aligned}}}
Sources: en.wikipedia.org
=== Learning and memory === The first learning and memory mutants (dunce, rutabaga, etc.) were isolated by William "Chip" Quinn while in Benzer's lab, and were eventually shown to encode components of an intracellular signaling pathway involving cyclic AMP, protein kinase A, and a transcription factor known as CREB. These molecules were shown to be also involved in synaptic plasticity in Aplysia and mammals. The initial report by William Quinn et al. described a basic conditioned preference assay. Over the next decade, the assay evolved into the classical olfactory conditioning paradigm in the T-maze: ~100 flies in a vial are connected to a short hallway that splits in two directions, a T-maze. On either end of the T-maze are two odors that are initially neutral, i.e. flies do not show preference for one odor or the other. The assay involves counting the number of flies in each side of the T-maze corridor. Before training half of the flies, on average, will before in each end. During training, the flies also encounter a stimulus in one of the two ends, typically either a sugar reward or an electric shock. After training, flies will show a preference for one odor or another. The two odors are referred to as the conditioned stimulus (CS), and the reward is the unconditioned stimulus (US). The T-maze assay was used to show where in the fly brain the association is made between the unconditioned stimulus and the conditioned stimulus. Olfactory sensory information is carried by antennal lobe projection neurons to the Kenyon cells of the mushroom body of the fly brain.
Polymyxins are antibiotics. Polymyxins B and E (also known as colistin) are used in the treatment of Gram-negative bacterial infections. They work mostly by breaking up the bacterial cell membrane. They are part of a broader class of molecules called nonribosomal peptides. They are produced in nature by Gram-positive bacteria such as Paenibacillus polymyxa.
=== Immigration Act of 1924 === Anti-miscegenation laws, along with the Immigration Act of 1924, contributed to the anti-immigrant sentiment that existed during the development of United States history. At this point in time, the United States was concerned with foreigners coming into the country in higher numbers and therefore enforced its first border patrol and regulated the number of foreign immigrants from south and eastern Europe, as well as permitting people from the southern people specialized in agriculture and work from the southern border. In the forgotten narrative of Latin American History, U.S., Mexican immigrants and citizens were labeled and seen as a problem in society because they were seen as hyper-fertile and supported theories that Mexicans were of a lower racial level. By the first half of the 20th century, almost 60,000 people had been sterilized under the different U.S. Eugenics Programs implemented.
=== Fl–Fu === Louis B. Flexner (1902–1996). American biochemist at the University of Pennsylvania, who worked on the biochemistry of memory and brain function. Member Natl. Acad. Sci. USA. Otto Folin (1867–1934). Swedish-American chemist at Harvard, best known for developing methods for the determination of the constituents of protein-free blood filtrates. Member Natl. Acad. Sci. USA. Karl August Folkers (1906–1997). American biochemist at Merck, known for work on the antibiotics cathomycin and cycloserine. Ivar Asbjørn Følling (1888–1973). Norwegian biochemist and geneticist who first described phenylketonuria. Sidney W. Fox (1912–1998). American biochemist at the University of Miami who worked on the production of amino acids in abiotic conditions. Heinz Fraenkel-Conrat (1910–1999). German-American biochemist at UC Berkeley, known for research on viruses such as tobacco mosaic virus. Member Natl. Acad. Sci. USA. Rosalind Franklin (1920–1958). British X-ray crystallographer at King's and Birkbeck Colleges, London, who worked on the structure of DNA Perry A. Frey (b. 1935). American biochemist at the University of Wisconsin known for work on enzyme mechanisms. Member Natl. Acad. Sci. USA. Irwin Fridovich (1929–2019). American biochemist at Duke University, who discovered superoxide dismutase and studied its mechanisms and superoxide toxicity. Member Natl. Acad. Sci. USA. Joseph S. Fruton (1912–2007). Polish-American biochemist at the Rockefeller Institute.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.